$HZNP News

Last published 1mo ago

1mo agoHZNPApproval of Tepezza, Bla #761143FDA Approved DrugsApproval Date: 09/23/2026; Drug Name: Tepezza, Bla #761143; Active Ingredients: TEPROTUMUMAB-TRBW; Company: Horizon Therapeutics Ireland; Submission Status: Approval; Application Number: 761143
1y agoAVTE DVAX HZNP MRNA+7Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies' Board of Directors at 2025 Annual MeetingBusiness WireIssues Letter to Fellow Shareholders Detailing Why Truly Independent Voices – Including a Shareholder Representative – Are Needed in the Dynavax Boardroom
3y agoHZNPRule 17(e) Announcement - Horizon Therapeutics plcBusiness WireNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH
3y agoHZNPRule 17(d) Announcement – Horizon Therapeutics plcBusiness WireNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH
3y agoHZNPRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)Business WireHorizon Therapeutics plc (NASDAQ:HZNP): IRISH TAKEOVER PANEL DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR, OFFEREE OR PARTIES ACTING IN
3y agoHZNPRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)Business WireIRISH TAKEOVER PANEL DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR, OFFEREE OR PARTIES ACTING IN CONCERT WITH THEM IN RESPECT OF DEALINGS
3y agoHZNPHorizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023Business Wire-- Presentations will feature data from the pivotal Phase 3 study of UPLIZNA, including new biomarker analyses -- Horizon Therapeutics plc (NASDAQ:HZNP) today announced that new UPLIZNA analyses will be presented at
3y agoHZNPRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)Business WireIRISH TAKEOVER PANEL DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR, OFFEREE OR PARTIES ACTING IN CONCERT WITH THEM IN RESPECT OF DEALINGS
3y agoHZNPNew Analysis Highlights Importance of Adhering to Uninterrupted Full Course of Treatment with TEPEZZA® (teprotumumab-trbw) to Support Thyroid Eye Disease (TED) Patient OutcomesBusiness Wire-- Additional data presented at ATA 2023 include a subgroup analysis from the TEPEZZA Phase 4 clinical trial and insights on the impact of TED on quality of life (QOL) -- Horizon Therapeutics plc (NASDAQ:HZNP) today
3y agoHZNPRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)Business WireIRISH TAKEOVER PANEL DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR, OFFEREE OR PARTIES ACTING IN CONCERT WITH THEM IN RESPECT OF DEALINGS
3y agoHZNPHorizon Therapeutics plc Named to U.S. News & World Report's 2024 List of Best Companies to Work For in the Health Care IndustryBusiness WireHorizon Therapeutics plc (NASDAQ:HZNP) today announced that it has been named to U.S. News & World Report's 2024 list of Best Companies to Work For in the Health Care Industry, ranking among the top companies
3y agoHZNPRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)Business WireIRISH TAKEOVER PANEL DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR, OFFEREE OR PARTIES ACTING IN CONCERT WITH THEM IN RESPECT OF
3y agoHZNPHorizon Therapeutics plc Ranks Number One on the Fortune Best Workplaces in Biopharma 2023 ListBusiness WireHorizon Therapeutics plc (NASDAQ:HZNP) announced it has been named No. 1 on the Fortune Best Workplaces in Biopharma 2023 list in the large company category. This is the seventh consecutive year Horizon has been named
3y agoHZNPQ32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia AreataBusiness Wire-- Alopecia areata is the second autoimmune indication being evaluated for bempikibart -- Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon
3y agoHZNPQ32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia AreataPR Newswire-- Alopecia areata is the second autoimmune indication being evaluated for bempikibart -- WALTHAM, Mass. and DUBLIN, Sept. 13, 2023 /PRNewswire/ -- Q32 Bio, a clinical stage biotechnology company developing biologic
3y agoHZNPHorizon Therapeutics plc ("Horizon") Rule 2.12 AnnouncementBusiness WireNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION In accordance
3y agoHZNPHorizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of ArrangementBusiness WireNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH
3y agoAMGN HZNPAMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITIONPR NewswireTHOUSAND OAKS, Calif. and DUBLIN, Sept. 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Horizon Therapeutics plc (NASDAQ:HZNP) today announced the entry into a consent order agreement with the Federal Trade Commission
3y agoAMGN HZNPAmgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close AcquisitionBusiness WireAmgen (NASDAQ:AMGN) and Horizon Therapeutics plc (NASDAQ:HZNP) today announced the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This
3y agoHZNP AMGNFTC allows Amgen to move forward with $27.8 billion Horizon Therapeutics acquisitionCNBCThe FTC had filed a lawsuit in May seeking to block the acquisition, arguing that the deal would "stifle competition" in the pharmaceutical industry.
3y agoHZNPHorizon Therapeutics plc Ranks First in Overall Corporate Reputation by Rare Disease Patient Advocacy GroupsBusiness WireHorizon Therapeutics plc (NASDAQ:HZNP) today announced that it ranked first in overall corporate reputation among rare disease patient groups around the world who were familiar with the company. Rare disease patient
3y agoHZNPHorizon Therapeutics plc - Rule 2.12 AnnouncementBusiness WireNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION In accordance
3y agoHZNPHorizon Therapeutics plc Reports Second-Quarter 2023 Financial ResultsBusiness WireSecond-Quarter 2023 Results: -- Net Sales of $945.0 Million, Representing Year-Over-Year Growth of 11% Excluding Inflammation Medicines -- -- GAAP Net Income of $127.1 Million; Adjusted EBITDA of $320.4 Million -- --
3y agoAMZN AAPL AMGN HZNP+13Jim Cramer's top 10 things to watch in the stock market FridayCNBCAmazon's (AMZN) second-quarter results Thursday gave investors exactly what they wanted, while Apple (AAPL) showed the power of its services business.
3y agoHZNPRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)Business WireHorizon Therapeutics plc (NASDAQ:HZNP): IRISH TAKEOVER PANEL DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR, OFFEREE OR PARTIES ACTING IN
3y agoHZNPHorizon Therapeutics plc Announces Phase 2 Trial Evaluating Daxdilimab for the Treatment of Systemic Lupus Erythematosus (SLE) Did Not Meet Primary EndpointBusiness Wire- The Company continues to assess the full dataset; daxdilimab trials in alopecia areata, discoid lupus erythematosus and lupus nephritis ongoing – Horizon Therapeutics plc (NASDAQ:HZNP) today announced that its Phase
3y agoHZNPHorizon Therapeutics plc to Release Second-Quarter 2023 Financial Results on Aug. 8, 2023Business WireHorizon Therapeutics plc (NASDAQ:HZNP) announced today that it will release its second-quarter 2023 financial results on Tuesday, Aug. 8, 2023, prior to the open of the U.S. financial markets. With the pending
3y agoHZNPLong-Term Data From the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection With Methotrexate Published in ACR Open RheumatologyBusiness Wire-- Month 12 data reinforce durable efficacy of co-treatment approach -- Horizon Therapeutics plc (NASDAQ:HZNP) today announced the publication of the long-term data from the MIRROR randomized controlled clinical trial
3y agoHZNPNew Analysis of MRI Findings Shows UPLIZNA® (inebilizumab-cdon) Reduced the Formation of Subclinical Spinal Cord Lesions in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)Business Wire-- Study shows subclinical spinal cord lesions were associated with future NMOSD attacks -- Horizon Therapeutics plc (NASDAQ:HZNP) today announced the presentation of a new analysis of MRI data from the Phase 3
3y agoHZNPHorizon Therapeutics plc Announces Positive Topline Data from Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)Business Wire-- At Week 24, 89% of patients treated with TEPEZZA had a clinically meaningful improvement in proptosis (≥2 mm) compared with 11% of patients receiving placebo -- Horizon Therapeutics plc (NASDAQ:HZNP) today
3y agoACCO BY GCMG HZNP+4NIRI Chicago Elects 2023-2024 Officers and DirectorsBusiness WireThe Chicago chapter of NIRI, The Association for Investor Relations (NIRI Chicago), has elected 13 officers and directors to its board for the 2023-2024 term, effective July 1. "NIRI Chicago offers an outstanding
3y agoHZNPAdditional Data from Phase 4 TEPEZZA® (teprotumumab-trbw) Clinical Trial Presented at the Endocrine Society Annual Meeting Reinforces Efficacy in People with Thyroid Eye Disease (TED) Regardless of Disease Activity or DurationBusiness Wire-- Data at Week 24 show 2.41 mm reduction in proptosis in patients treated with TEPEZZA compared with 0.92 mm in those who received placebo; 62% of TEPEZZA patients had clinically meaningful improvement in proptosis (≥2
3y agoHZNPNew Data from TEPEZZA® (teprotumumab-trbw) Clinical Trials and Real-World Analyses Shed Light on Link Between Thyroid Autoimmunity and Hearing RisksBusiness WireHorizon Therapeutics plc (NASDAQ:HZNP) today announced the presentation of a series of analyses demonstrating the risk of hearing-related events among people with Graves' disease and TED, including among those treated
3y agoHZNPHorizon Therapeutics plc ("Horizon") Rule 2.12 AnnouncementBusiness WireIn accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the "Irish Takeover Rules"), Horizon confirms that, as of the close of business on June 9, 2023, Horizon's issued ordinary share
3y agoHZNPUPLIZNA® (inebilizumab-cdon) Pivotal Trial Publication Integrating MRI and Biomarker Evaluation Shows Accuracy and Uniformity of Attack Diagnoses for Neuromyelitis Optica Spectrum Disorder (NMOSD)Business Wire-- Findings published in the Multiple Sclerosis Journal provide early validation of a process that could inform new clinical standards to improve attack diagnosis and treatment decision-making -- Horizon Therapeutics
3y agoHZNPHorizon Therapeutics plc announces premium partnership with KPMG Women's Irish OpenBusiness WireHorizon Therapeutics plc (NASDAQ:HZNP) today announced its partnership for the 2023 KPMG Women's Irish Open held at Dromoland Castle from August 31 to September 3. The leading Ladies European Tour (LET) event tees up a
3y agoHZNPHorizon Therapeutics plc Announces Data from the TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low CAS Thyroid Eye Disease (TED) to be Presented at the Upcoming Endocrine Society (ENDO) Annual MeetingBusiness Wire-- TEPEZZA Phase 4 trial results to be shared in an oral presentation on Saturday, June 17 at 3:30 p.m. CT -- -- Two patients will share their real-world experience living with TED and being treated with TEPEZZA on
3y agoHZNPRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)Business WireHorizon Therapeutics plc (NASDAQ:HZNP): IRISH TAKEOVER PANEL DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR, OFFEREE OR PARTIES ACTING IN
3y agoHZNPBiomarker Analysis Publication Highlights Key Signals of Disability Worsening Associated With Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks, Illustrates Efficacy of UPLIZNA® (inebilizumab-cdon)Business Wire-- Analysis in The Journal of Neurology, Neurosurgery and Psychiatry demonstrate the direct effect of UPLIZNA on levels of sNFL and sGFAP, two key biomarkers strongly associated with NMOSD attacks and disability
3y agoHZNPPresentations at the 2023 EULAR European Congress of Rheumatology Highlight New Results from Phase 2 Trial Evaluating Dazodalibep in Sjögren's SyndromeBusiness Wire-- Only Sjögren's syndrome Phase 2 trial to meet the primary endpoint in both patient population types -- -- Patients with moderate-to-severe systemic disease activity (ESSDAI score ≥5) treated with dazodalibep
3y agoHZNPNew Analyses of the MIRROR Randomized Controlled Trial in Uncontrolled Gout Presented at the 2023 EULAR European Congress of RheumatologyBusiness Wire-- New data illustrate impact of KRYSTEXXA® (pegloticase) injection with methotrexate to improve patient outcomes and clinical measures for uncontrolled gout -- Horizon Therapeutics plc (NASDAQ:HZNP) today
3y agoHZNPHorizon Therapeutics plc Announces Presentation of Data that Advances the Understanding of Rheumatic Diseases at the 2023 EULAR European Congress of RheumatologyBusiness Wire-- Phase 2 results for dazodalibep in Sjögren's syndrome to be presented on June 1, 11:35-11:45 a.m. CEST and June 3, 9:35-9:45 a.m. CEST -- -- Planned presentations illustrate Horizon's momentum in raising standards
3y agoHZNP AMGNHorizon Therapeutics says Amgen deal could close earlier than planned if FTC fails to block itCNBCThe new timeline is earlier than what Amgen, Horizon Therapeutics and Wall Street analysts were initially expecting after the FTC sued to block the deal.
3y agoPFE SGEN CVS AAPL+9Pfizer to raise $31 billion in debt offering to fund Seagen acquisition, SEC filing showsCNBCThe debt offering by Pfizer to buy cancer drug maker Seagen comes as Apple, Merck and T-Mobile tap the U.S. bond market ahead of the debt ceiling standoff.
3y agoHZNP RH HD COF+11Stocks making the biggest moves midday: Horizon Therapeutics, Capital One, RH, Home Depot and moreCNBCThese are the stocks posting the largest moves midday.
3y agoHZNPHorizon Therapeutics plc Responds to U.S. Federal Trade Commission (FTC) Action to Block Acquisition by AmgenBusiness WireHorizon Therapeutics plc (NASDAQ:HZNP) today issued the following statement in response to the FTC's complaint seeking to block Amgen's proposed acquisition of the Company: "This acquisition has the potential to
3y agoAMGN HZNPHorizon Therapeutics stock plunges on report FTC is preparing to block Amgen dealCNBCThe deal is bid to strengthen Amgen's drug portfolio as it prepares to face several patent expirations for key treatments over the next decade.
3y agoHZNPRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)Business WireHorizon Therapeutics plc (NASDAQ:HZNP): IRISH TAKEOVER PANEL DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR, OFFEREE OR PARTIES ACTING IN
3y agoHZNPHorizon Therapeutics plc Ranks First in Overall Corporate Reputation by U.S. Patient Advocacy GroupsBusiness WireHorizon Therapeutics plc (NASDAQ:HZNP) today announced that it ranked first in overall corporate reputation among U.S. patient groups who reported working with, or who were familiar with the company. The results are
3y agoHZNPHorizon Therapeutics plc ("Horizon") - Rule 2.12 AnnouncementBusiness WireIn accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the "Irish Takeover Rules"), Horizon confirms that, as of the close of business on March 31, 2023, Horizon's issued ordinary